Ozempic for Type 2 Diabetes — How It Helps - The Molecular Mimic

Julia Cartwright breaks down how semaglutide activates GLP-1 receptors to stimulate glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and protect pancreatic beta cells in type 2 diabetes. We explore the molecular engineering behind its 168-hour half-life, clinical trial data showing 1–1.8% A1C reductions, and why this precision-designed peptide is reshaping diabetes treatment beyond metformin. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.